Skip to main content
Top
Published in: Calcified Tissue International 6/2021

Open Access 01-12-2021 | Computed Tomography | Original Research

Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

Authors: Sarah E. Warner, Frederick S. Kaplan, Robert J. Pignolo, Stacy E. Smith, Edward C. Hsiao, Carmen De Cunto, Maja Di Rocco, Kathleen Harnett, Donna Grogan, Harry K. Genant

Published in: Calcified Tissue International | Issue 6/2021

Login to get access

Abstract

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disorder that leads to heterotopic ossification (HO), resulting in progressive restriction of physical function. In this study, low-dose, whole-body computed tomography (WBCT) and dual energy X-ray absorptiometry (DXA) were evaluated to determine the preferred method for assessing total body burden of HO in patients with FOP. This was a non-interventional, two-part natural history study in patients with FOP (NCT02322255; date of registration: December 2014). In Part A (described here), WBCT and DXA scans were individually assessed for HO presence and severity across 15 anatomical regions. All images were independently reviewed by an expert imaging panel. Ten adult patients were enrolled across four sites. The sensitivity to HO presence and severity varied considerably between the two imaging modalities, with WBCT demonstrating HO in more body regions than DXA (76/138 [55%] versus 47/113 [42%]) evaluable regions). Inability to evaluate HO presence, due to overlapping body regions (positional ambiguity), occurred less frequently by WBCT than by DXA (mean number of non-evaluable regions per scan 1.2 [standard deviation: 1.5] versus 2.4 [1.4]). Based on the increased sensitivity and decreased positional ambiguity of low-dose WBCT versus DXA in measuring HO in patients with FOP, low-dose WBCT was chosen as the preferred imaging for measuring HO. Therefore, low-dose WBCT was carried forward to Part B of the natural history study, which evaluated disease progression over 36 months in a larger population of patients with FOP.
Literature
1.
go back to reference Shore EM, Feldman GJ, Xu M, Kaplan FS (2005) The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3:201–204CrossRef Shore EM, Feldman GJ, Xu M, Kaplan FS (2005) The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 3:201–204CrossRef
2.
go back to reference Baujat G, Choquet R, Bouée S, Jeanbat V, Courouve L, Ruel A, Michot C, Le Quan Sang KH, Lapidus D, Messiaen C, Landais P, Cormier-Daire V (2017) Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis 12:123CrossRef Baujat G, Choquet R, Bouée S, Jeanbat V, Courouve L, Ruel A, Michot C, Le Quan Sang KH, Lapidus D, Messiaen C, Landais P, Cormier-Daire V (2017) Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis 12:123CrossRef
3.
go back to reference Kaplan FS, Pignolo RJ, Shore EM (2009) The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev 20:399–407CrossRef Kaplan FS, Pignolo RJ, Shore EM (2009) The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev 20:399–407CrossRef
4.
go back to reference Kaplan FS, Xu M, Seemann P, Connor M, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Köster B, Pauli RM, Reardon W, Zaidi SA, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM (2009) Classic and atypical FOP phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 30:379–390CrossRef Kaplan FS, Xu M, Seemann P, Connor M, Glaser DL, Carroll L, Delai P, Fastnacht-Urban E, Forman SJ, Gillessen-Kaesbach G, Hoover-Fong J, Köster B, Pauli RM, Reardon W, Zaidi SA, Zasloff M, Morhart R, Mundlos S, Groppe J, Shore EM (2009) Classic and atypical FOP phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 30:379–390CrossRef
5.
go back to reference Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38:525–527CrossRef Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38:525–527CrossRef
6.
go back to reference Meyers C, Lisiecki J, Miller S, Levin A, Fayad L, Ding C, Sono T, McCarthy E, Levi B, James AW (2019) Heterotopic ossification: a comprehensive review. JBMR Plus 3:e10172CrossRef Meyers C, Lisiecki J, Miller S, Levin A, Fayad L, Ding C, Sono T, McCarthy E, Levi B, James AW (2019) Heterotopic ossification: a comprehensive review. JBMR Plus 3:e10172CrossRef
7.
go back to reference Ortiz-Agapito F, Colmenares-Bonilla D (2015) Quality of life of patients with fibrodysplasia ossificans progressiva. J Child Orthop 9:489–493CrossRef Ortiz-Agapito F, Colmenares-Bonilla D (2015) Quality of life of patients with fibrodysplasia ossificans progressiva. J Child Orthop 9:489–493CrossRef
8.
go back to reference Di Rocco M, Baujat G, Bertamino M, Brown M, De Cunto CL, Delai PLR, Eekhoff EMW, Haga N, Hsiao E, Keen R, Morhart R, Pignolo RJ, Kaplan FS (2017) International physician survey on management of FOP: a modified Delphi study. Orphanet J Rare Dis 12:110CrossRef Di Rocco M, Baujat G, Bertamino M, Brown M, De Cunto CL, Delai PLR, Eekhoff EMW, Haga N, Hsiao E, Keen R, Morhart R, Pignolo RJ, Kaplan FS (2017) International physician survey on management of FOP: a modified Delphi study. Orphanet J Rare Dis 12:110CrossRef
9.
go back to reference Kaplan FS, Pignolo RJ, Al Mukaddam M, Shore EM (2019) Genetic disorders of heterotopic ossification: fibrodysplasia ossificans progressiva and progressive osseous heteroplasia. In: Bilezikian JP (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 9th edn. Wiley, Washington, D.C., pp 865–870 Kaplan FS, Pignolo RJ, Al Mukaddam M, Shore EM (2019) Genetic disorders of heterotopic ossification: fibrodysplasia ossificans progressiva and progressive osseous heteroplasia. In: Bilezikian JP (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 9th edn. Wiley, Washington, D.C., pp 865–870
10.
go back to reference Kaplan FS, Pignolo RJ, Al Mukaddam MM, Shore EM (2017) Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opin Orphan Drugs 5:291–294CrossRef Kaplan FS, Pignolo RJ, Al Mukaddam MM, Shore EM (2017) Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opin Orphan Drugs 5:291–294CrossRef
11.
go back to reference Pignolo RJ, Shore EM, Kaplan FS (2013) Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev 10(Suppl 2):437–448PubMedPubMedCentral Pignolo RJ, Shore EM, Kaplan FS (2013) Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev 10(Suppl 2):437–448PubMedPubMedCentral
12.
go back to reference Kaplan FS, Al Mukaddam M, Baujat G, Brown M, Cali A, Cho T-J, Crowe C, De Cunto C, Delai P, Diecidue R, Di Rocco M, Eekhoff EMW, Friedman C, Grunwald Z, Haga N, Hsiao E, Keen R, Kitterman J, Levy C, Morhart R, Netelenbos C, Scott C, Shore EM, Zasloff M, Zhang K, Pignolo RJ (2019) The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. IFOPA https://www.ifopa.org/updated_fop_treatment_guidelines_released. Accessed 5 Nov 2020 Kaplan FS, Al Mukaddam M, Baujat G, Brown M, Cali A, Cho T-J, Crowe C, De Cunto C, Delai P, Diecidue R, Di Rocco M, Eekhoff EMW, Friedman C, Grunwald Z, Haga N, Hsiao E, Keen R, Kitterman J, Levy C, Morhart R, Netelenbos C, Scott C, Shore EM, Zasloff M, Zhang K, Pignolo RJ (2019) The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. IFOPA https://​www.​ifopa.​org/​updated_​fop_​treatment_​guidelines_​released. Accessed 5 Nov 2020
14.
go back to reference Al Mukaddam M, Rajapakse CS, Pignolo RJ, Kaplan FS, Smith SE (2018) Imaging assessment of fibrodysplasia ossificans progressiva: qualitative, quantitative and questionable. Bone 109:147–152CrossRef Al Mukaddam M, Rajapakse CS, Pignolo RJ, Kaplan FS, Smith SE (2018) Imaging assessment of fibrodysplasia ossificans progressiva: qualitative, quantitative and questionable. Bone 109:147–152CrossRef
15.
go back to reference Hashemi J, Shahfarhat A, Beheshtian A (2011) Fibrodysplasia ossificans progressiva: report of a case and review of articles. Iran J Radiol 8:113–117CrossRef Hashemi J, Shahfarhat A, Beheshtian A (2011) Fibrodysplasia ossificans progressiva: report of a case and review of articles. Iran J Radiol 8:113–117CrossRef
16.
go back to reference Zhang W, Zhang K, Song L, Pang J, Ma H, Shore EM, Kaplan FS, Wang P (2013) The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone 57:386–391CrossRef Zhang W, Zhang K, Song L, Pang J, Ma H, Shore EM, Kaplan FS, Wang P (2013) The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone 57:386–391CrossRef
17.
go back to reference Kaplan FS, Strear CM, Zasloff MA (1994) Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res (304):238–247 Kaplan FS, Strear CM, Zasloff MA (1994) Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res (304):238–247
18.
go back to reference Rogoveanu O, Traistaru R, Streba CT, Stoica Z, Popescu R (2013) Clinical, evolution and therapeutical considerations upon a case of fibrodysplasia ossificans progressiva (FOP). J Med Life 6:454–458PubMedPubMedCentral Rogoveanu O, Traistaru R, Streba CT, Stoica Z, Popescu R (2013) Clinical, evolution and therapeutical considerations upon a case of fibrodysplasia ossificans progressiva (FOP). J Med Life 6:454–458PubMedPubMedCentral
19.
go back to reference Kulwin R, Binkovitz LA (2009) PET/CT of fibrodysplasia ossificans progressiva. Pediatr Radiol 39:991–994CrossRef Kulwin R, Binkovitz LA (2009) PET/CT of fibrodysplasia ossificans progressiva. Pediatr Radiol 39:991–994CrossRef
20.
go back to reference Botman E, Raijmakers PGHM, Yaqub M, Teunissen B, Netelenbos C, Lubbers W, Schwarte LA, Micha D, Bravenboer N, Schoenmaker T, de Vries TJ, Pals G, Smit JM, Koolwijk P, Trotter DG, Lammertsma AA, Eekhoff EMW (2019) Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: an [18F]NaF PET/CT study. Bone 124:1–6CrossRef Botman E, Raijmakers PGHM, Yaqub M, Teunissen B, Netelenbos C, Lubbers W, Schwarte LA, Micha D, Bravenboer N, Schoenmaker T, de Vries TJ, Pals G, Smit JM, Koolwijk P, Trotter DG, Lammertsma AA, Eekhoff EMW (2019) Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: an [18F]NaF PET/CT study. Bone 124:1–6CrossRef
21.
go back to reference ALARA Principle (2008) In: Baert AL (ed) Encyclopedia of diagnostic imaging. Springer, Berlin, Heidelberg ALARA Principle (2008) In: Baert AL (ed) Encyclopedia of diagnostic imaging. Springer, Berlin, Heidelberg
22.
go back to reference Kaplan FS, Al Mukaddam M, Pignolo RJ (2017) A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone 101:123–128CrossRef Kaplan FS, Al Mukaddam M, Pignolo RJ (2017) A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone 101:123–128CrossRef
23.
go back to reference Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS (1993) The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am 75:215–219CrossRef Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, Sando N, Zasloff M, Kaplan FS (1993) The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am 75:215–219CrossRef
24.
go back to reference Pignolo RJ, Bedford-Gay C, Liljesthröm M, Durbin-Johnson BP, Shore EM, Rocke DM, Kaplan FS (2016) The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res 31:650–656CrossRef Pignolo RJ, Bedford-Gay C, Liljesthröm M, Durbin-Johnson BP, Shore EM, Rocke DM, Kaplan FS (2016) The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res 31:650–656CrossRef
25.
go back to reference Pignolo RJ, Durbin-Johnson BP, Rocke DM, Kaplan FS (2018) Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP). Bone 109:124–133CrossRef Pignolo RJ, Durbin-Johnson BP, Rocke DM, Kaplan FS (2018) Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP). Bone 109:124–133CrossRef
26.
go back to reference Hsiao EC, Di Rocco M, Cali A, Zasloff M, Al Mukaddam M, Pignolo RJ, Grunwald Z, Netelenbos C, Keen R, Baujat G, Brown MA, Cho TJ, De Cunto C, Delai P, Haga N, Morhart R, Scott C, Zhang K, Diecidue RJ, Friedman CS, Kaplan FS, Eekhoff EMW (2019) Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol 85:1199–1207CrossRef Hsiao EC, Di Rocco M, Cali A, Zasloff M, Al Mukaddam M, Pignolo RJ, Grunwald Z, Netelenbos C, Keen R, Baujat G, Brown MA, Cho TJ, De Cunto C, Delai P, Haga N, Morhart R, Scott C, Zhang K, Diecidue RJ, Friedman CS, Kaplan FS, Eekhoff EMW (2019) Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol 85:1199–1207CrossRef
27.
go back to reference Binkovitz LA, Henwood MJ (2007) Pediatric DXA: technique and interpretation. Pediatr Radiol 37:21–31CrossRef Binkovitz LA, Henwood MJ (2007) Pediatric DXA: technique and interpretation. Pediatr Radiol 37:21–31CrossRef
28.
go back to reference Shepherd J, Ng B, Sommer M, Heymsfield SB (2017) Body composition by DXA. Bone 104:101–105CrossRef Shepherd J, Ng B, Sommer M, Heymsfield SB (2017) Body composition by DXA. Bone 104:101–105CrossRef
29.
go back to reference Pignolo RJ, Shore EM, Kaplan FS (2011) Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis 6:80CrossRef Pignolo RJ, Shore EM, Kaplan FS (2011) Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis 6:80CrossRef
30.
go back to reference Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT (2009) Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med 50:1570–1577CrossRef Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT (2009) Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med 50:1570–1577CrossRef
31.
go back to reference Horger M, Claussen CD, Bross-Bach U, Vonthein R, Trabold T, Heuschmid M, Pfannenberg C (2005) Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 54:289–297CrossRef Horger M, Claussen CD, Bross-Bach U, Vonthein R, Trabold T, Heuschmid M, Pfannenberg C (2005) Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 54:289–297CrossRef
33.
go back to reference Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, Keen R, Al Mukaddam M, Sang KLQ, Wilson A, White B, Grogan DR, Kaplan FS (2019) Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis 14:98CrossRef Pignolo RJ, Baujat G, Brown MA, De Cunto C, Di Rocco M, Hsiao EC, Keen R, Al Mukaddam M, Sang KLQ, Wilson A, White B, Grogan DR, Kaplan FS (2019) Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis 14:98CrossRef
Metadata
Title
Whole-body Computed Tomography Versus Dual Energy X‑ray Absorptiometry for Assessing Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva
Authors
Sarah E. Warner
Frederick S. Kaplan
Robert J. Pignolo
Stacy E. Smith
Edward C. Hsiao
Carmen De Cunto
Maja Di Rocco
Kathleen Harnett
Donna Grogan
Harry K. Genant
Publication date
01-12-2021
Publisher
Springer US
Published in
Calcified Tissue International / Issue 6/2021
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-021-00877-6

Other articles of this Issue 6/2021

Calcified Tissue International 6/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine